Tag: technology

REVEAL Ultra Cellular Trail Camera is Company’s Most Feature-Rich Product to Date

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Stingray (TSX: RAY. A; RAY.B), an industry leader in music and video content distribution, business services, and advertising solutions, proudly announces its contribution in the grand opening of BMO's new branch at CF Toronto Eaton Centre. This state-of-the-art, full-service branch features Stingray Business's cutting-edge digital signage solutions, highlighting the integration of advanced technology in customer experiences.

The BMO branch in the CF Toronto Eaton Centre is strategically located on the corner of Yonge and  Dundas near Sankofa Square, one of Toronto's busiest intersections and a vibrant hub of innovation and activity. Its two-story wraparound windows presented a unique opportunity to elevate BMO’s brand presence, showcase an innovative approach to marketing, while maintaining a welcoming and comfortable customer experience within the branch. To maximize this unique opportunity, BMO partnered with Stingray Business to implement an innovative digital signage solution.

Potential strategic alliance aims to transform residential real estate accessibility and transaction efficiency through exclusive integration of MiiX’s proprietary platform across La Rosa’s network

BEIJING, June 12, 2025 (GLOBE NEWSWIRE) -- The “International Editors-in-Chief Roundtable,” co-hosted by Global Times and Global Times Online (huanqiu.com), was recently held, bringing together editors-in-chief from China, Latin America, and around the world. Centered on the theme of "Harmony and Integration" Approach to China–Latin America Civilizational Exchange, the forum called for enhanced cross-cultural dialogue and practical cooperation to jointly build a more balanced and inclusive international media landscape.

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.